Welcome to our dedicated page for Cerevel Therapeutics Hldng news (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Hldng stock.
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) is a clinical-stage biopharmaceutical leader pioneering neuroscience therapies for central nervous system disorders. This page serves as the definitive source for official company announcements, research milestones, and financial updates.
Investors and industry observers will find curated press releases covering clinical trial progress, regulatory developments, strategic partnerships, and quarterly results. Our aggregation ensures timely access to material information about CERE's neuropharmacology pipeline targeting Parkinson's, Alzheimer's, and schizophrenia.
All content is verified at source to maintain compliance with financial disclosure standards. Bookmark this page for streamlined tracking of Cerevel's advancements in receptor-specific therapies and neuroscience innovation.
AbbVie (NYSE: ABBV) has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE), strengthening its neuroscience portfolio. The acquisition brings multiple clinical-stage assets, including emraclidine, a potential best-in-class antipsychotic for schizophrenia, and tavapadon, a first-in-class treatment for Parkinson's disease. AbbVie expects the acquisition to be accretive to adjusted diluted EPS beginning in 2030.
The company reaffirms its 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91, which includes a $0.19 per share dilutive impact from the Cerevel acquisition. AbbVie also maintains its third-quarter adjusted diluted EPS guidance range of $2.92-$2.96. The acquisition is expected to contribute to AbbVie's long-term performance and complement its existing neuroscience pipeline.
BFA LLP has announced an investigation into the merger between Cerevel Therapeutics (NASDAQ: CERE) and AbbVie. Under the merger terms, AbbVie will buy all outstanding shares of Cerevel for $45.00 per share in cash, valuing the company at approximately $8.7 billion. This transaction, approved by the boards of directors of both companies, is set to close in mid-2024. BFA LLP suspects that Cerevel's board was conflicted and agreed to an unfair price for shareholders. Shareholders may have legal options and can obtain more information or legal representation on a contingency fee basis by visiting BFA's website or contacting them directly.
FAQ
What is the current stock price of Cerevel Therapeutics Hldng (CERE)?
What is the market cap of Cerevel Therapeutics Hldng (CERE)?
